Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
Business Wire•16/11/2026•09:00 ET
0
Key Highlights
- ➤Phase 2a AKI study expected to deliver topline data in late 2027
- ➤Study cost approximately $7 million versus $60 million previously
- ➤Revelation plans licensing and development partnerships for Gemini
- ➤Gemini targets a $94 billion acute kidney injury market
- ➤Revelation held $9.1 million in cash and equivalents as of September 30, 2026
Expert Statements
James Rolke, Chairman and Chief Executive Officer of Revelation Biosciences
“Gemini’s ability to regulate inflammation through multiple pathways represents a potentially important advance in treating acute kidney injury”
James Rolke, Chairman and Chief Executive Officer of Revelation Biosciences
“Our revised strategy is designed to generate meaningful clinical data sooner, with substantially less capital, while positioning Gemini for potential strategic partnerships.”
Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
New streamlined Phase 2a study in acute kidney injury expected to deliver topline data in 2027 at nearly 90% lower costs than original clinical milestone
Get started
Create a free account to read the full story.
